$DARE
Dare Bioscience, Inc. Stock $dare

$dare Overview Financials Valuation SEC Filings Company Website

2020 Form 10-K Financial Statement

#000140191421000041 Filed on March 30, 2021

Income Statement

Concept	2020	2019 Q4	2019
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.630M	$1.490M	$5.800M
YoY Change	14.31%	14.62%	9.85%
% of Gross Profit
Research & Development	$20.77M	$2.370M	$8.546M
YoY Change	143.03%	42.77%	33.24%
% of Gross Profit
Depreciation & Amortization	$43.23K	$10.00K	$11.14K
YoY Change	288.14%		356.43%
% of Gross Profit
Operating Expenses	$27.40M	$3.860M	$14.34M
YoY Change	91.02%	30.41%	-15.03%
Operating Profit	-$27.40M		-$14.34M
YoY Change	91.02%		-15.03%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$1.514K	-$10.00K	$81.05K
YoY Change	-98.13%	-125.0%	-43.52%
Pretax Income	-$27.40M	-$3.870M	-$13.80M
YoY Change	98.56%	32.53%	-17.4%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$27.40M	-$3.870M	-$14.26M
YoY Change	92.1%	32.53%	-14.79%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.91
Diluted Earnings Per Share	-$0.91	-$214.4K	-$915.3K
COMMON SHARES
Basic Shares Outstanding	30.09M shares	16.68M shares
Diluted Shares Outstanding	30.09M shares

Balance Sheet

Concept	2020	2019 Q4	2019
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.670M	$4.780M	$4.780M
YoY Change	-2.3%	-29.81%	-29.81%
Cash & Equivalents	$4.670M	$4.780M	$4.780M
Short-Term Investments
Other Short-Term Assets	$1.850M	$1.110M	$1.110M
YoY Change	66.67%		177.5%
Inventory
Prepaid Expenses		$1.109M
Receivables
Other Receivables		$555.2K
Total Short-Term Assets	$6.980M	$6.444M	$6.440M
YoY Change	8.39%	-11.0%	-11.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$280.0K	$63.53K	$550.0K
YoY Change	-49.09%	576.15%	5400.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$290.0K	$935.3K	$450.0K
YoY Change	-35.56%	61.83%	-22.41%
Total Long-Term Assets	$570.0K	$998.9K	$1.000M
YoY Change	-43.0%	70.06%	69.49%
TOTAL ASSETS
Total Short-Term Assets	$6.980M	$6.444M	$6.440M
Total Long-Term Assets	$570.0K	$998.9K	$1.000M
Total Assets	$7.550M	$7.443M	$7.440M
YoY Change	1.48%	-4.91%	-4.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.020M	$1.083M	$1.080M
YoY Change	-5.56%	135.63%	134.78%
Accrued Expenses	$3.710M	$2.099M	$2.510M
YoY Change	47.81%	232.41%	298.41%
Deferred Revenue
YoY Change
Short-Term Debt	$370.0K	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.660M	$5.612M	$5.610M
YoY Change	36.54%	414.4%	414.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.040M	$389.6K	$1.390M
YoY Change	-25.18%	3911.49%	13800.0%
Total Long-Term Liabilities	$1.040M	$389.6K	$1.390M
YoY Change	-25.18%	3911.49%	13800.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.660M	$5.612M	$5.610M
Total Long-Term Liabilities	$1.040M	$389.6K	$1.390M
Total Liabilities	$8.700M	$7.002M	$7.000M
YoY Change	24.29%	536.1%	536.36%
SHAREHOLDERS EQUITY
Retained Earnings		-$44.02M
YoY Change		51.96%
Common Stock		$44.57M
YoY Change		24.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.150M	$440.8K	$440.0K
YoY Change
Total Liabilities & Shareholders Equity	$7.550M	$7.443M	$7.440M
YoY Change	1.48%	-4.91%	-4.98%

Cashflow Statement

Concept	2020	2019 Q4	2019
OPERATING ACTIVITIES
Net Income	-$27.40M	-$3.870M	-$14.26M
YoY Change	92.1%	32.53%	-14.79%
Depreciation, Depletion And Amortization	$43.23K	$10.00K	$11.14K
YoY Change	288.14%		356.43%
Cash From Operating Activities	-$25.23M	-$3.810M	-$13.32M
YoY Change	89.52%	40.59%	29.67%
INVESTING ACTIVITIES
Capital Expenditures	$17.63K	$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$6.140M	$6.140M
YoY Change	-100.0%		-1303.92%
Cash From Investing Activities	-$17.63K	$6.140M	$6.144M
YoY Change	-100.29%		-1284.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$22.98M		$5.152M
YoY Change	346.02%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$25.13M	0.000	$5.152M
YoY Change	387.81%		-49.05%
NET CHANGE
Cash From Operating Activities	-$25.23M	-3.810M	-$13.32M
Cash From Investing Activities	-$17.63K	6.140M	$6.144M
Cash From Financing Activities	$25.13M	0.000	$5.152M
Net Change In Cash	-$110.6K	2.330M	-$2.026M
YoY Change	-94.54%	-185.98%	168.69%
FREE CASH FLOW
Cash From Operating Activities	-$25.23M	-$3.810M	-$13.32M
Capital Expenditures	$17.63K	$0.00	$0.00
Free Cash Flow	-$25.25M	-$3.810M	-$13.32M
YoY Change	89.65%	40.59%	29.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001401914
CY2020	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:OtherAssetsNoncurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-36395
CY2020	dei	Entity Registrant Name EntityRegistrantName	DARÉ BIOSCIENCE, INC.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-4139823
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	3655 Nobel Drive
CY2020	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 260
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92122
CY2020	dei	City Area Code CityAreaCode	858
CY2020	dei	Local Phone Number LocalPhoneNumber	926-7655
CY2020	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.0001 Per Share
CY2020	dei	Trading Symbol TradingSymbol	DARE
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	22800000	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	47312822	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4669467	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1108615	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	6983912	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	6443932	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4780107	USD
CY2020Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	460168	USD
CY2019Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	555210	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1854277	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37930	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	63531	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	528870	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	935325	USD
CY2020Q4	us-gaap	Assets Assets	7550712	USD
CY2019Q4	us-gaap	Assets Assets	7442788	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1021333	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1083183	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3359718	USD
CY2019Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2098653	USD
CY2020Q4	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	1564553	USD
CY2019Q4	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	2019674	USD
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	367285	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	1000000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	347712	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	410896	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7660601	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5612406	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1000000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1000000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	41844	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	389556	USD
CY2020Q4	us-gaap	Liabilities Liabilities	8702445	USD
CY2019Q4	us-gaap	Liabilities Liabilities	7001962	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41596253	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41596253	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19683401	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19683401	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	4159	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1968	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-91388	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-102625	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	70366293	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	44564674	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71430797	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-44023191	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-1151733	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	440826	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7550712	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7442788	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6549508	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5265438	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20769416	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8546108	USD
CY2020	dare	License Fee LicenseFee	83333	USD
CY2019	dare	License Fee LicenseFee	533334	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	27402257	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	14344880	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-27402257	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-14344880	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1514	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	81050	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-27400743	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-14263830	USD
CY2020	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	6863	USD
CY2019	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	789594	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27407606	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15053424	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	11237	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5897	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27396369	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15059321	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.91
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.97
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30091469	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15578959	shares
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	6726620	USD
CY2019	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2369992	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	462239	USD
CY2020	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	1785979	USD
CY2020	dare	Stock Issued During Period Value Consideration For Commitment To Purchase Shares StockIssuedDuringPeriodValueConsiderationForCommitmentToPurchaseShares	291529	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-14263830	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5897	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	440826	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	22977407	USD
CY2020	us-gaap	Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued	1825000	shares
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	742031	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-27400743	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	11237	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-1151733	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-27400743	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-14263830	USD
CY2020	us-gaap	Depreciation Depreciation	43227	USD
CY2019	us-gaap	Depreciation Depreciation	11137	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	742031	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	462239	USD
CY2020	dare	Non Cash Lease Expense NonCashLeaseExpense	-162167	USD
CY2019	dare	Non Cash Lease Expense NonCashLeaseExpense	-29121	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	-202096	USD
CY2020	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-95042	USD
CY2019	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	201423	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	454133	USD
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	322482	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-157725	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-237937	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-61850	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	608650	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1261065	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	621618	USD
CY2020	dare	Increase Decrease In Deferred Grant Funding IncreaseDecreaseInDeferredGrantFunding	455121	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1000000	USD
CY2019	dare	Increase Decrease In Deferred Grant Funding IncreaseDecreaseInDeferredGrantFunding	238109	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25234924	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13315480	USD
CY2020	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2019	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	6143893	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17625	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17625	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6143893	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	22977407	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5151702	USD
CY2020	dare	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	1785979	USD
CY2019	dare	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	367285	USD
CY2019	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25130672	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5151702	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11237	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-5897	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	583697	USD
CY2020	dare	Issuance Cost On Equity Paid In Common Stock IssuanceCostOnEquityPaidInCommonStock	291529	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-110640	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2025782	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4780107	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6805889	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4669467	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4780107	USD
CY2019	dare	Issuance Cost On Equity Paid In Common Stock IssuanceCostOnEquityPaidInCommonStock	0	USD
CY2020	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	6863	USD
CY2019	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	789594	USD
CY2020	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	0	USD
CY2019	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	2369992	USD
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71400000	USD
CY2020Q4	dare	Working Capital Increase Deficit WorkingCapitalIncreaseDeficit	-700000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-27400000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-25200000	USD
CY2020	dare	Periodof Insufficient Cashand Liquidity Requirements PeriodofInsufficientCashandLiquidityRequirements	P12M
CY2020Q4	dare	Grant Funding Recognized During Period GrantFundingRecognizedDuringPeriod	3700000	USD
CY2019Q4	dare	Grant Funding Recognized During Period GrantFundingRecognizedDuringPeriod	1300000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of stock-based compensation, and purchase accounting. Actual results could differ from those estimates and could materially affect the reported amounts of assets, liabilities and future operating results.</span></div>
CY2020Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	35903	USD
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains cash balances at various financial institutions and such balances commonly exceed the $250,000 amount insured by the Federal Deposit Insurance Corporation. The Company also maintains money market funds at various financial institutions which are not federally insured although are invested primarily in the U.S. The Company has not experienced any losses in such accounts and management believes that the Company does not have significant risk with respect to such cash and cash equivalents.</span></div>
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1300000	USD
CY2020	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Obligations</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law, the Company has entered into indemnification agreements with its officers and directors that provide that the Company will indemnify its directors and officers for certain expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by such director or officer in any action or proceeding arising out of their service as a director and/or officer. The term of the indemnification is for the officer’s or director’s lifetime. During the year ended December 31, 2020, the Company did not experience any losses related to those indemnification obligations. The Company does not expect significant claims related to these indemnification obligations, and consequently, has concluded the fair value of the obligations is not material. Accordingly, as of December 31, 2020 and 2019, no amounts have been accrued related to such indemnification provisions.</span></div>
CY2020Q4	dare	Accrued Indemnification Provisions AccruedIndemnificationProvisions	0	USD
CY2019Q4	dare	Accrued Indemnification Provisions AccruedIndemnificationProvisions	0	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	227298	USD
CY2020Q4	dare	Prepaid Professional Expense PrepaidProfessionalExpense	338638	USD
CY2019Q4	dare	Prepaid Professional Expense PrepaidProfessionalExpense	386328	USD
CY2019Q4	us-gaap	Prepaid Insurance PrepaidInsurance	417152	USD
CY2020Q4	dare	Prepaid Clinical Expense PrepaidClinicalExpense	1288341	USD
CY2019Q4	dare	Prepaid Clinical Expense PrepaidClinicalExpense	305135	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1854277	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1108615	USD
CY2019Q4	dare	Accrued License Expense AccruedLicenseExpense	280833	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2894
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0001
CY2020Q4	dare	Prepaid Insurance Noncurrent PrepaidInsuranceNoncurrent	246016	USD
CY2019Q4	dare	Prepaid Insurance Noncurrent PrepaidInsuranceNoncurrent	404141	USD
CY2020Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	43304	USD
CY2019Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	42904	USD
CY2020Q4	dare	Operating Lease Right Of Use Asset Noncurrent OperatingLeaseRightOfUseAssetNoncurrent	239550	USD
CY2019Q4	dare	Operating Lease Right Of Use Asset Noncurrent OperatingLeaseRightOfUseAssetNoncurrent	488280	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	528870	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	935325	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1157074	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	715201	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	297395	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	412584	USD
CY2020Q4	dare	Accrued License Expense AccruedLicenseExpense	66667	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1838582	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	690035	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3359718	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2098653	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-27249000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-13800000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-152000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-464000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-27401000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-14264000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0886
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0701
CY2020	dare	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0
CY2019	dare	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.0002
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0180
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0146
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0034
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0044
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.0040
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.3093
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0002
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	68437000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	46120000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4903000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3669000	USD
CY2020Q4	dare	Deferred Tax Assets Capitalized Research And Development Cost DeferredTaxAssetsCapitalizedResearchAndDevelopmentCost	9398000	USD
CY2019Q4	dare	Deferred Tax Assets Capitalized Research And Development Cost DeferredTaxAssetsCapitalizedResearchAndDevelopmentCost	11123000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	376000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	271000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2183000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1987000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	85297000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	63170000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	85297000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	63170000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4100000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	200000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	78100000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	85300000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	63200000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	22100000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	935000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	924000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	237000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	83000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	169000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	72000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1341000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	935000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1300000	USD
CY2018Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.00
CY2020Q4	dare	Unremitted Earnings UnremittedEarnings	0	USD
CY2020Q2	dare	Saleof Stock Maximum Amount Registered SaleofStockMaximumAmountRegistered	7500000	shares
CY2020Q4	dare	Deferred Offering Costs Unamortized Portion DeferredOfferingCostsUnamortizedPortion	175000	USD
CY2019Q2	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.98
CY2020Q3	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.96
CY2019Q2	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	800000	USD
CY2020Q3	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	6863	USD
CY2020	dare	Number Of Common Stock Warrants Exercised NumberOfCommonStockWarrantsExercised	1825000	shares
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1800000	USD
CY2019	dare	Number Of Common Stock Warrants Exercised NumberOfCommonStockWarrantsExercised	0	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1908643	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	742031	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	462239	USD
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41596253	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41596253	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19683401	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19683401	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5199750	shares
CY2020Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	1300000	USD
CY2020	dare	Weighted Average Amortization Period WeightedAverageAmortizationPeriod	P2Y2M12D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0082
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0244
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.20
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.20
CY2020	dare	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.000
CY2019	dare	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.00
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.75
CY2018Q3	us-gaap	Net Rentable Area NetRentableArea	3169	sqft
CY2018Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P1Y
CY2018Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.07
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	42000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	303800	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	223000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	461000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y10M9D
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	363000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	42000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	405000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	16000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	389000	USD
CY2020Q2	dare	Coronavirus Aid Reliefand Economic Security Act Loan Proceeds Received CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived	367000	USD
CY2020Q4	dare	Notes Payable Current Plus Accrued Interest NotesPayableCurrentPlusAccruedInterest	369600	USD
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	136000	USD
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	96000	USD
	dare	Proceeds From Award Of Grant ProceedsFromAwardOfGrant	1900000	USD
CY2020Q2	dare	Proceeds From Award Of Grant ProceedsFromAwardOfGrant	731000	USD
CY2020Q4	us-gaap	Grants Receivable GrantsReceivable	12000	USD
CY2020Q4	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	1600000	USD

Files In Submission

Name	View Source	Status
0001401914-21-000041-index-headers.html	Edgar Link	pending
0001401914-21-000041-index.html	Edgar Link	pending
0001401914-21-000041.txt	Edgar Link	pending
0001401914-21-000041-xbrl.zip	Edgar Link	pending
dare-20201231.htm	Edgar Link	pending
dare-20201231.xsd	Edgar Link	pending
dare-20201231xex211.htm	Edgar Link	pending
dare-20201231xex231.htm	Edgar Link	pending
dare-20201231xex311.htm	Edgar Link	pending
dare-20201231xex312.htm	Edgar Link	pending
dare-20201231xex321.htm	Edgar Link	pending
dare-20201231xex322.htm	Edgar Link	pending
dare-20201231_cal.xml	Edgar Link	unprocessable
dare-20201231_def.xml	Edgar Link	unprocessable
dare-20201231_g1.jpg	Edgar Link	pending
dare-20201231_g2.jpg	Edgar Link	pending
dare-20201231_htm.xml	Edgar Link	completed
dare-20201231_lab.xml	Edgar Link	unprocessable
dare-20201231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DARE
Dare Bioscience, Inc. Stock $dare

2020 Form 10-K Financial Statement

#000140191421000041 Filed on March 30, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE Dare Bioscience, Inc. Stock $dare

2020 Form 10-K Financial Statement

#000140191421000041 Filed on March 30, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE
Dare Bioscience, Inc. Stock $dare